Video
When sick patients entrust their hopes of recovery to emerging cell therapies, cell collections and research teams have vital roles to play. In this video, Simone Steiner, Head of Technical Development and Manufacturing at Tigen Pharma SA, reveals how starting materials impact the efficacy of cell therapy products and ultimately patient outcomes.
Uncover the link between apheresis and clinical results.
Presentation
As cell and gene therapies gain traction around the globe, biotech and life science researchers and hospital cell collection teams have a vested common interest: ensuring the highest-quality starting materials with minimal variability for the greatest chance of therapeutic success. Optimizing collections comes down to three key points that play out across the cell collections ecosystem.
Discover how the pieces fit together.
Every research and cell therapy process and endpoint come with specific requirements, but no two patients are exactly alike. For too long, this perceived conflict has prevented biotech and life science organizations from sourcing cell products that truly meet their needs. That’s all changing thanks to the power of data analytics unlocking key insights from apheresis procedure data. Our Spectra Optia Prediction Algorithm service, which sets cell collection targets against benchmarks based on an individual patient’s precount, is just one example of how process standardization can boost overall quality and consistency as it helps improve patient experience.
Find out the difference analytics can make.
All products and solutions may not be available in all regions. Contact your Terumo Blood and Cell Technologies representative.